{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-24-000081","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.245596+00:00","generated_at":"2026-06-02T06:44:58.394989+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GoodRx Q1 2024 revenue $197.9M; adjusted EBITDA $62.8M","bullets":["Revenue (GAAP and adjusted) of $197.9M; net loss $1.0M; adjusted net income $32.6M.","Adjusted EBITDA $62.8M (31.7% margin); operating cash flow $42.6M.","Exited Q1 with ~8 million consumers of prescription-related offerings.","Interim CEO Scott Wagner cites progress and path to return to 'Rule of 40' company."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-24-000081","json":"https://secwatch.observer/filing/0001809519-24-000081.json","markdown":"https://secwatch.observer/filing/0001809519-24-000081.md","text":"https://secwatch.observer/filing/0001809519-24-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000081/0001809519-24-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000081/gdrx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:44:58.394989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cbd3aa19c2b0d8ee3d7f50a9fda91a13fd494d75","claim":"GoodRx Holdings, Inc. reported the three months ended March 31, 2024 results: revenue $197.9 million, net income Net loss of $1.0 million.","evidence_excerpt":"for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights • Revenue 1 and Adjusted Revenue 1 of $197.9 million • Net loss of $1.0 million; Net loss margin of 0.5% • Adjusted Net Income 1 of $32.6 million; Adjusted Net Income Margin 1 of 16.5% • Adjusted EBITDA 1 of $62.8 million; Adjusted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000081/0001809519-24-000081-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$197.9 million"},{"label":"Net income","value":"Net loss of $1.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}